CFB
NBIX icon

Cullen/Frost Bankers’s Neurocrine Biosciences NBIX Stock Holding History

Cullen/Frost Bankers’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.8K Buy
+260
New +$38.6K ﹤0.01% 898
2020
Q4 		– Sell
-6
Closed -$1K – 1143
2020
Q3 		$1K Buy
+6
New +$694 ﹤0.01% 1104
2020
Q1 		– Sell
-85
Closed -$9K – 984
2019
Q4 		$9K Sell
85
-135
-61% -$14.1K ﹤0.01% 904
2019
Q3 		$20K Buy
+220
New +$20.6K ﹤0.01% 720

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
AS
Aware Super Sydney, Australia $7.06B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

Cullen/Frost Bankers's NBIX Position: Q2 2026 in Review

Cullen/Frost Bankers opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 260 shares worth $43.8K. The stake represents ﹤0.01% of the portfolio and ranks #898 among its holdings. This is a return to the name: Cullen/Frost Bankers previously reported a position in NBIX as recently as Q3 2020.

Cullen/Frost Bankers first reported a position in NBIX in Q3 2019 and has held it in 4 quarters since. 260 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Cullen/Frost Bankers held 260 shares of Neurocrine Biosciences worth $43.8K as of Q2 2026.
  • Neurocrine Biosciences was a new Cullen/Frost Bankers position in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #898 holding.
  • Cullen/Frost Bankers first reported a position in Neurocrine Biosciences in Q3 2019 and has held it in 4 quarters since.
  • 260 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.